HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Michael A Schwarzschild Selected Research

Caffeine (No Doz)

3/2013Caffeine consumption and risk of dyskinesia in CALM-PD.
9/2012Caffeine and risk of Parkinson's disease in a large cohort of men and women.
8/2012Caffeine in Parkinson disease: better for cruise control than snooze patrol?
3/2012Prospective study of statin use and risk of Parkinson disease.
2/2012Adenosine A2A receptor gene disruption protects in an α-synuclein model of Parkinson's disease.
1/2011Deletion of adenosine A₁ or A(₂A) receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease.
6/2010Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration.
8/2006Adenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosis.
1/2006Cross-sensitization between caffeine- and L-dopa-induced behaviors in hemiparkinsonian mice.
1/2006Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Michael A Schwarzschild Research Topics

Disease

55Parkinson Disease (Parkinson's Disease)
10/2015 - 02/2002
8Dyskinesias (Dyskinesia)
01/2014 - 12/2003
5Nerve Degeneration
05/2014 - 08/2003
4Parkinsonian Disorders (Parkinsonism)
01/2014 - 12/2009
3Neurodegenerative Diseases (Neurodegenerative Disease)
01/2015 - 05/2012
3Disease Progression
01/2013 - 01/2005
2Urolithiasis
02/2014 - 01/2013
2Gout
02/2014 - 01/2013
2Tremor (Tremors)
08/2013 - 03/2003
2Alzheimer Disease (Alzheimer's Disease)
01/2013 - 01/2009
2Atrophy
01/2012 - 03/2003
2Gliosis
12/2009 - 03/2003
2Inflammation
01/2008 - 08/2006
1Huntington Disease (Huntington's Disease)
01/2015
1Weight Loss (Weight Reduction)
01/2014
1Lewy Body Disease (Lewy Body Dementia)
01/2013
1Hypercholesterolemia
03/2012
1Hypertension (High Blood Pressure)
09/2010
1Restless Legs Syndrome (Restless Legs)
04/2009
1Obesity
04/2009
1Liver Cirrhosis (Hepatic Cirrhosis)
08/2006
1Pulmonary Fibrosis (Hamman Rich Syndrome)
08/2006
1Fibrosis (Cirrhosis)
08/2006
1Ischemia
09/2003
1Reperfusion Injury
09/2003
1Dystonia (Limb Dystonia)
03/2003
1Dementia (Dementias)
03/2003
1Wounds and Injuries (Trauma)
06/2002
1Anoxia (Hypoxia)
06/2002

Drug/Important Bio-Agent (IBA)

16Uric Acid (Urate)IBA
10/2015 - 04/2008
13Caffeine (No Doz)FDA LinkGeneric
03/2013 - 09/2002
11Adenosine A2A Receptor (Adenosine A2A Receptors)IBA
08/2013 - 06/2002
10Dopamine (Intropin)FDA LinkGeneric
01/2015 - 12/2003
8Levodopa (L Dopa)FDA LinkGeneric
01/2014 - 02/2002
7AdenosineFDA LinkGeneric
01/2011 - 06/2002
61- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA
01/2015 - 09/2002
4SynucleinsIBA
09/2015 - 10/2011
4Purinergic P1 Receptors (Adenosine Receptor)IBA
02/2012 - 06/2002
3alpha-SynucleinIBA
01/2015 - 03/2003
3Adenosine A2 Receptor AntagonistsIBA
03/2013 - 01/2005
2Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)IBA
09/2015 - 08/2011
2Biological Markers (Surrogate Marker)IBA
10/2013 - 01/2008
2HormonesIBA
10/2013 - 09/2010
2purineIBA
01/2013 - 06/2008
2Glutamic Acid (Glutamate)FDA Link
05/2012 - 12/2010
2rasagiline (Azilect)FDA Link
11/2010 - 02/2010
2Estrogens (Estrogen)FDA Link
07/2009 - 01/2006
1Allopurinol (Remid)FDA LinkGeneric
05/2014
1InosineFDA Link
02/2014
12- fluoro- 6- (tetrahydrofuran- 3- ylamino)- 4- (3,6,6- trimethyl- 4- oxo- 4,5,6,7- tetrahydro- 1H- indol- 1- yl)benzamideIBA
01/2014
1Particulate MatterIBA
01/2014
1Cholecalciferol (Vitamin D3)FDA Link
10/2013
1Pilocarpine (Ocusert)FDA LinkGeneric
08/2013
1CoffeeFDA Link
03/2013
1pramipexol (pramipexole)FDA LinkGeneric
03/2013
1Neurotransmitter Agents (Neurotransmitter)IBA
05/2012
13,9-bis((ethylthio)methyl)-K-252aIBA
08/2011
1Ibuprofen (Motrin)FDA LinkGeneric
03/2011
1Oxidopamine (6 Hydroxydopamine)IBA
12/2010
1metabotropic glutamate receptor 5IBA
12/2010
1Calcium Channels (Calcium Channel)IBA
09/2010
1Calcium Channel Blockers (Blockers, Calcium Channel)IBA
09/2010
1DiureticsIBA
09/2010
1ManebIBA
06/2010
1ParaquatIBA
06/2010
15- amino- 7- (2- phenylethyl)- 2- (2- furyl)pyrazolo(4,3- e)- 1,2,4- triazolo(1,5- c)pyrimidineIBA
12/2009
1Selegiline (E250)FDA LinkGeneric
12/2009
1Monoamine Oxidase (MAO)IBA
01/2009
1Interleukin-6 (Interleukin 6)IBA
01/2008
1Dopamine Agents (Dopaminergic Agents)IBA
10/2006
1ZM 241385 (ZM241385)IBA
08/2006
1Thioacetamide (Thioacetamid)IBA
08/2006
1istradefyllineIBA
01/2005
1Vitamin B 6IBA
08/2004
1Folic Acid (Vitamin M)FDA LinkGeneric
08/2004
1Vitamin B 12 (Cyanocobalamin)FDA LinkGeneric
08/2004
1HomocysteineIBA
08/2004
1Vitamin B Complex (B Vitamins)IBA
08/2004
1Phosphotransferases (Kinase)IBA
01/2004
1N-Methylaspartate (NMDA)IBA
01/2004
1Dopamine Agonists (Dopamine Agonist)IBA
12/2003
1Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA
08/2003
1Purinergic P1 Receptor AntagonistsIBA
04/2003
1Carisoprodol (Soma)FDA LinkGeneric
03/2003
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
06/2002
1P-2 (P 2)IBA
06/2002
1Interferon-gamma (Interferon, gamma)IBA
06/2002
1Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA
06/2002
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
06/2002

Therapy/Procedure

2Therapeutics
01/2015 - 08/2007
1Drug Therapy (Chemotherapy)
01/2009